STRO vs SVRA

Sutro Biopharma, Inc. vs Savara, Inc. — Valuation Comparison 2026

STRO

Biotechnology
Sutro Biopharma, Inc.
Quality
5.6
out of 10
Value Trap
24
SAFE
Price
$29.63
Last close
Models
8/13
Active
VS

SVRA

Biotechnology
Savara, Inc.
Quality
4.5
out of 10
Value Trap
30
LOW
Price
$5.09
Last close
Models
7/13
Active

Model-by-Model Comparison

ModelType STRO Fair ValueSTRO Upside SVRA Fair ValueSVRA Upside
Bayesian DCF Intrinsic $7.89 -73.4% $1.41 -72.2%
First Chicago Scenario $•••.•• ••.•% $•••.•• ••.•%
ML-RIV Intrinsic $7.27 -75.5% $0.40 -92.2%
Dynamic NAV Asset-Based $4.73 -84.0% $0.93 -81.7%
PWERM Option-Based $•••.•• ••.•% $•••.•• ••.•%
Regime Cross-Sectional Relative $•••.•• ••.•% $•••.•• ••.•%
Sentiment SOTP Hybrid $•••.•• ••.•% $•••.•• ••.•%
CUCE Ensemble Ensemble $•••.•• ••.•% $•••.•• ••.•%
🔒

Unlock Full 13-Model Comparison

Access all valuation models for STRO vs SVRA — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

STRO vs SVRA — Which Stock Is More Undervalued?

STRO scores higher with a 5.6/10 quality rating vs SVRA's 4.5/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Sutro Biopharma, Inc. (STRO) and Savara, Inc. (SVRA) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

STRO currently trades at $29.63 with a QOC of 5.6/10, while SVRA trades at $5.09 with a QOC of 4.5/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).